Paper Details

  1. Home
  2. Paper Details

Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report.

Author: FiteniFréderic, GeTony, GirardNicolas, GuilhaumeMarie-Noëlle, PautasMarie, ThomasQuentin Dominique

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Enteral administration of alectinib should be considered for elderly patients with an impaired general condition who have lung cancer with oncogenic addiction.
Paper Details　
Original Abstract of the Article :
RATIONALE: Alectinib is a tyrosine kinase inhibitor (TKI) approved for use as first-line metastatic therapy for patients with anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Certain medical conditions related to the tumor lesions may not allow oral administration of TKIs. PATIENT ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556033/

データ提供：米国国立医学図書館（NLM）

Alectinib: A New Oasis in the Desert of ALK-Positive Lung Cancer Treatment

The field of non-small cell lung cancer (NSCLC) treatment is constantly evolving, seeking to provide effective and personalized care for patients. This case report explores the use of alectinib, a tyrosine kinase inhibitor (TKI), for treating ALK-positive NSCLC in an elderly patient with swallowing difficulties. The authors describe the challenges of administering alectinib orally in this patient and highlight the feasibility and potential benefits of enteral administration.

Enteral Alectinib: A Potential Solution for Specific Patients

The study found that enteral administration of alectinib was well-tolerated and resulted in a significant clinical and radiological response in the patient. The patient experienced few side effects and showed a substantial reduction in tumor size, along with improvements in cognitive function and overall health status.

Health Implications

This case report highlights the potential benefits of enteral administration of TKIs in patients with ALK-positive NSCLC who cannot tolerate oral medication due to swallowing difficulties or other medical conditions. It underscores the importance of considering alternative routes of administration to ensure optimal treatment outcomes.

Dr.Camel's Conclusion

This case report explores a potential oasis in the desert of ALK-positive NSCLC treatment, demonstrating the feasibility and potential benefits of enteral administration of alectinib in specific patients. The findings suggest that this approach may offer a valuable alternative for patients who cannot tolerate oral medication, potentially improving treatment outcomes and enhancing patient quality of life.

Date :
  1. Date Completed 2021-11-05
  2. Date Revised 2023-01-03
Further Info :

Pubmed ID

34713842

DOI: Digital Object Identifier

PMC8556033

Related Literature

Article Analysis
・Side Effects of alectinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.